TOR1A/TorsinA mutations cause poorly explained neurological diseases. A dominantly inherited mutation causes isolated dystonia, while biallelic mutations cause a recessive infant-onset syndrome with cases of lethality. Here we report an unexpected connection between lipid metabolism and these diseases. Lipin phosphatidic acid phosphatase activity was abnormally regulated in TorsinA dystonia patient cells, and in the brains of three different TorsinA disease model mice. Lipin activity was causative to symptoms given that lowering Lipin1 in vivo strongly intervened against lethality in disease mice. Furthermore, Lipin hyperactivity caused cell death in vitro, and Lipin1 deficiency suppressed neurodegeneration in vivo. In addition, it protected the striatal cholinergic interneurons that are implicated in TorsinA movement disorders, and concomitantly suppressed abnormal motor behaviors of TorsinA mice. These data establish the central role of Lipin lipid enzyme hyperactivity in TorsinA disease and show that Lipin inhibition is a therapeutic target for these incurable conditions. One Sentence Summary: Lipin inhibition rescues TorsinA neurological disease TOR1A/TorsinA mutations cause at least two neurological diseases.
Abstract:
TOR1A/TorsinA mutations cause poorly explained neurological diseases. A dominantly inherited mutation causes isolated dystonia, while biallelic mutations cause a recessive infant-onset syndrome with cases of lethality. Here we report an unexpected connection between lipid metabolism and these diseases. Lipin phosphatidic acid phosphatase activity was abnormally regulated in TorsinA dystonia patient cells, and in the brains of three different TorsinA disease model mice. Lipin activity was causative to symptoms given that lowering Lipin1 in vivo strongly intervened against lethality in disease mice. Furthermore, Lipin hyperactivity caused cell death in vitro, and Lipin1 deficiency suppressed neurodegeneration in vivo. In addition, it protected the striatal cholinergic interneurons that are implicated in TorsinA movement disorders, and concomitantly suppressed abnormal motor behaviors of TorsinA mice. These data establish the central role of Lipin lipid enzyme hyperactivity in TorsinA disease and show that Lipin inhibition is a therapeutic target for these incurable conditions. One Sentence Summary: Lipin inhibition rescues TorsinA neurological disease TOR1A/TorsinA mutations cause at least two neurological diseases.
Dominantly inherited TOR1A/TorsinA dystonia (OMIM #128100) caused by the +/E mutation is characterized by childhood-onset involuntary twisting movements and abnormal postures of unexplained origin (1) . Indeed, despite many years of study, no structural or degenerative pathology has been found to explain this isolated dystonia.
It is the most common hereditary dystonia, and the genetic insult is a widely used experimental tool to investigate mechanisms leading to dystonia. However, it also remains poorly understood at molecular, cellular and neurobiology system levels.
There is also a recessive TorsinA syndrome with a broader set of symptoms. This emerges at birth, and is caused by TorsinA E/E or other biallelic combinations of TorsinA deletions (2) (3) (4) (5) . Affected infants invariably show arthrogryposis (joint contractures at birth), tremor, and develop speech, cognition and motor deficits.
There is no cure for either TorsinA disease. Dominant TorsinA dystonia symptoms often develop into severe, generalized dystonia that is highly debilitating and interferes with all aspects of daily life. It is typically managed with deep brain stimulation. However, this is invasive and often fails to provide full symptom relief. The alternative is botulinum toxin treatment of affected muscle groups if the dystonia remains focal or segmental, but this is also purely symptomatic and only partially effective. There are even fewer options for recessive syndrome patients, and there are examples where infants failed to survive even in high-level health care settings. The surviving children continue to suffer from severe neurological defects, including intellectual impairment, and require continuous support and care (2) (3) (4) (5) .
Poor understanding of disease molecular and cellular pathology is rate-limiting for translating information on the genetic cause into therapies. TorsinA is an ATPase that resides in the endoplasmic reticulum (ER) (6, 7) . In turn, the ER operates in membrane protein quality control, calcium buffering, and lipid synthesis, while specialized ER domains like the nuclear envelope have additional functions. Torsin AAA+ enzymes have been shown to affect the three core ER functions, as well as several at the nuclear envelope, with the nature and severity of torsin loss-of-function phenotypes varying between cell types and experimental paradigms (8) (9) (10) (11) (12) (13) (14) . This is in fact explainable by the inter-dependent nature of different ER functions (15) . However, unfortunately, it means we lack information on which defects are primary to TorsinA mutation(s) and, more importantly, which are causative for disease and thus should be targeted for therapy.
The ability to dissect disease cause(s) has been particularly challenging because TorsinA diseases are defined by their behavioral symptoms. Thus, any suspected cause must be interrogated against behavioral abnormalities. This is difficult since animal models appear to tolerate the dominant E/+ mutation that causes dystonia in humans, while mice with recessive syndrome mutations (-/-, -/E and E/E knock-in) die as neonates ( Figure 1A ) (16, 17) . More recently, a conditional TorsinA mouse model was developed that has features of both diseases. This carries one copy of TorsinA E and one floxed TorsinA allele. In vivo expression of Crerecombinase reduces the flox/E genotype to biallelic -/E: a recessive syndrome genotype. However, for as yet undetermined reasons, Cre expression during nervous system appears to most strongly impact animal movement, including causing dystonia-like symptoms reminiscent of those in TorsinA dystonia patients (18, 19).
Here we refer to this model as the "cKO/E" mouse.
Here we use three TorsinA mouse models (-/-, E/E and cKO/E) to examine the mammalian and nervous system relevance of our previous finding that Drosophila dTorsin regulates lipid synthesis. We focused on the hypothesized underlying mechanism in flies: regulation of phosphatidic acid (PtdA) dephosphorylation (12) . This enzymatic reaction is mediated by Lipin or LPP enzymes, is a key step in de novo lipid synthesis, and produces the DAG signaling lipid ( Figure 1B) (15) . We now show that the Lipin phosphatidic acid phosphatase (PAP) enzyme is hyperactive in TorsinA -/-, E/E, and cKO/E mouse brains. TorsinA also synergizes with TorsinB to regulate Lipin, and this underlies why a non-neuronal TorsinA cell line has normal Lipin activity. In line with this, knock down of TorsinB reveals abnormal Lipin activity in nonneuronal human patient cells with TorsinA mutations. Moreover, we establish in vivo that Lipin has a pathogenic role in TorsinA-associated neurodegeneration, motor dysfunction and animal lethality, and see that these phenotypes are rescuable by even partial reduction in Lipin hyperactivity. In conclusion, these data establish that Lipin hyperactivity is key in TorsinA neurological diseases, and that Lipin inhibition has strong therapeutic potential for these currently incurable conditions.
Results
We previously demonstrated that fly dTorsin loss affects lipid synthesis in the larval fat body (12) . However, another study failed to find lipidomic defects in mammalian cells (20) . We now compared the brain lipidome of embryonic day 18.5 (E18.5) wild-type versus TorsinA E/E, or -/-littermates. This also revealed similar bulk steady-state glycerophospholipid levels (Supplemental Figure 1A -F) . However, steady-state lipidomics lacks resolution to detect transient and/ or localized differences in lipid levels, particularly for low abundance lipids. It also provides little information on the rate of lipid enzyme reactions. We therefore specifically examined the metabolic reaction most effected by fly dTorsin loss: PtdA dephosphorylation to DAG ( Figure   1B ). Animals have two classes of PAP enzymes: Lipins in the ER, and Lipid-phosphate phosphatases (LPPs) in other regions of the cell ( Figure 1B) (15) . We confirmed both activities were present in embryonic brain lysates ( Figure 1C , Supplemental Figure   1G ) and examined whether either was affected by recessive TorsinA disease mutations. This revealed ~3-fold elevated Lipin-mediated PAP activity in E/E and -/-brains compared to wild-types of the same litters ( Figure 1D ). In contrast, LPP enzyme activity was normal ( Figure 1E ). Thus, TorsinA indeed regulates brain lipid metabolism, and this function is affected by disease-causing genotypes.
Lipin also operates as a cofactor of PPAR transcription factors (21). We examined whether TorsinA also regulates this function by profiling gene expression in TorsinA mutant mouse brains. This found that PPAR genes and their targets were similarly expressed in +/+ and E/E brain (Supplemental Figure 2 and 3) . We also examined Lipin gene expression to determine whether elevated enzyme activity originated from elevated transcription. Of the 3 mammalian Lipin genes, Lipin1 and Lipin2 transcripts were detected in embryonic brains ( Figure 1F ). Lipin1 expression was mildly elevated in the E/E brain compared to wild-types ( Figure 1F ), and positively correlated with elevated enzyme activity ( Figure 1G & H) . However, Lipin1 expression levels overlapped substantially between wild-type and E/E embryos, and differences were minor compared to altered enzyme activity. We also examined expression of the Lipin regulatory proteins, Ctdnep1 and Cnep1r1 (22, 23), and again saw similar expression in wild-type and E/E TorsinA mutant brain ( Figure 1F ). Thus, it appears that TorsinA regulates brain Lipin PAP activity without altering its cotranscriptional function.
We next asked whether excess Lipin activity contributes to disease. We approached this in vivo in cKO/E mice where Nestin-Cre creates the KO allele during nervous system development ( Figure 1A and 2A) . This is shown to produce animals that survive past birth and develop behavioral impairments like those of dominant and recessive TorsinA disease patients (18). Similar to lipin activity in E/E and -/-brains, we again confirmed Lipin was hyperactive in cKO/E mice: at E18.5 their brain Lipin activity was ~2-fold higher than littermate controls ( Figure 2B ). We then modulated cKO/E Lipin PAP activity by genetically reducing Lipin1 expression ( Figure 2B ) (24).
Complete Lipin1/LIPIN1 loss is lethal in mouse and causes muscle disease in human (24-26), and thus we focused on physiologically tolerated Lipin1+/-. This was sufficient to reduce cKO/E brain Lipin hyperactivity, although it was still significantly higher than that of controls.
We proceeded to test whether Lipin hyperactivity contributed to neurological defects in the cKO/E mouse model ( Figure 2C ). Our first observation was that cKO/E animals were more severely affected than previously reported. While their weight was normal at birth, they immediately failed to thrive ( Figure 2D & E) and only ~20% survived to postnatal day 30 (P30; Figure 2F ). This is in fact consistent with other studies where Nestin-Cre drives a TorsinA loss-of-function mutation (27). It also mimics the symptoms of recessive TorsinA neonates who require immediate medical intervention and a proportion fail to survive (2) (3) (4) (5) . Strikingly, Lipin1+/-very strongly promoted cKO/E survival ( Figure 2F ). Indeed, the majority of cKO/E survived if they were deficient for Lipin1 ( Figure 2F ). Further, cKO/E animals stabilized once they survived to P30, and thus Lipin1+/-deficiency appeared to provide a permanent benefit ( Figure 2F ). Examination of kyphosis (hunchback) as a proxy for health of juvenile cKO/E mice also detected a benefit of Lipin1+/-loss ( Figure 2G ). This was significant even though almost double the number of "uncorrected" cKO/E mice had succumbed by this time point (53% and 27% loss of cKO/E with Lipin1+/+ vs.
Lipin1+/-, respectively). Thus, Lipin hyperactivity arising from TorsinA loss indeed plays a major role in the behavioral defects related to TorsinA recessive disease, and mild Lipin deficiency is sufficient to strongly improve survival of disease model mice.
The neurological defects of cKO/E mice occur alongside neurodegeneration (18, 19) and we examined whether Lipin is sufficient to cause cell death in cultured cells. We examined wild-type mouse Lipin1 overexpression, as well as Lipin1 that is catalytically dead for PAP activity. In addition, Lipin1 undergoes multi-site phosphorylation that inhibits activity and targets Lipin1 protein for degradation. We therefore included mutants where 17 Ser/Thr residues were exchanged to Ala and thus blocked inhibitory phosphorylation events (29, 30). The four Lipin1 cDNAs were electroporated, and cell survival assayed the following day. This identified that Lipin1 overexpression is cytotoxic when phosphorylatable residues are mutated, and a large proportion of this relates to Lipin catalytic activity ( Figure 3A) . We then examined whether Lipin hyperactivity contributes to cell death in vivo in cKO/E animals. We chose a juvenile developmental stage (P15) given the lethality of cKO/E animals with uncorrected Lipin ( Figure 2F ). We used activated caspase labeling to detect apoptotic cells and, since we did not detect obvious hotspots of apoptosis, quantified staining across the entire brain. This indeed detected elevated apoptotic staining in P15 cKO/E brain compared to wild-type or Lipin1+/-mice ( Figure 3B ). The elevated apoptotic labeling was significantly lower in "rescued" cKO/E:Lipin1+/-mice.
We then examined reactive gliosis as a second measure of in vivo degeneration. We focused on three brain nuclei where we confirmed previous reports that anti-GFAP detects this event in cKO/E (Nestin-Cre) animals; the facial nucleus We also assessed whether Lipin1 deficiency had benefit for animal motor function. We examined multiple aspects of cKO/E mice behavior and uncovered two aspects of impairment: a) a broad developmental delay (Figure 5A -5F) and b) the previously described motor dysfunction (18) (Figure 5G -5I). We then tested whether either or both was due to Lipin hyperactivity, and thus improved by Lipin deficiency.
The answer was negative for all neurodevelopmental measures, including those with ( Figure 5C and 5F) and without motor components (like response to auditory stimulus or eye opening; Figure 5D and 5E). In contrast, abnormal motor behaviors were sensitive to Lipin deficiency. We detected abnormal forelimb and hindlimb clasping, These data establish that Lipin hyperactivity is pathogenic for TorsinA disease symptoms in mice. They also raise questions about why these are neurological given that TorsinA and Lipins are broadly expressed (32, 33). In fact, Lipin activity was normal in TorsinA -/-embryonic liver and heart, as well as in E/E mouse embryonic fibroblasts (MEFs) ( Figure 6A ); the same animals that had ~3x Lipin activity in brain ( Figure 1D ). We investigated why, focusing on homologous Tor1b/TorsinB expression that, at least in some circumstances, appears to protect non-neuronal cells against TorsinA loss (7, 34, 35) . Indeed, Tor1b knock-down ( Figure 6B ) significantly increased Lipin activity in E/E MEFs, but not in +/+ ( Figure 6C ). Thus, torsinA and torsinB both regulate Lipin, and torsinB expression can mask the impact of torsinA loss. We then took advantage of this assay to ask whether TorsinA mice accurately model the biochemical landscape of human TorsinA disease. We electroporated human fibroblasts from controls (TorsinA +/+) and patients with TorsinA dystonia (genotype: +/E) with control or TOR1B shRNA ( Figure 6D and 6E). This efficiently suppressed TOR1B expression ( Figure 6D ) concomitant with significantly elevating Lipin activity in patient-derived cells but not in control cells ( Figure 6E ). Finally, we also examined Lipin activity in lysates of iPSC-derived neurons from two controls and two individuals with TorsinA dystonia that had been differentiated in parallel. The two patient samples had Lipin activity at 1.5 and 2.0 relative to the control ( Figure 6F ).
Discussion
These data establish a causative relationship between Lipin hyperactivity and the development of TorsinA disease. This conclusion comes from finding excess Lipin activity in neonatal-lethal homozygous TorsinA mice that genetically mimic recessive disease. It comes from finding that Lipin biochemistry is similarly altered in TorsinA patient and mouse fibroblasts, and that Lipin activity appears abnormal in iPSCderived neurons from TorsinA dystonia patients. Most importantly, it comes from the benefit of Lipin1 deficiency against lethality, neurodegeneration, and abnormal movements of a TorsinA disease model mouse. Indeed, the fact we intervene against behavioral dysfunction underlies why we assign a causative relationship between Lipin and diseases that are defined by their behavioral symptoms.
There are at least two different TorsinA diseases caused by different dosages of TorsinA mutation: +/E causes dominant TorsinA dystonia (1), while E/E (or other mutations) causes broad developmental delay, feeding, speech and motor problems, as well as lethality in some children (2-5). Here we focus on a conditional TorsinA disease mouse model that recapitulates features of both diseases. Firstly, considering its recessive disease symptoms, the mouse has perinatal and juvenile lethality, developmental delay, and tremor. These occur concomitant with neurodegeneration. We show that three of four phenotypes are strongly rescued by partial Lipin deficiency. Thus, Lipin inhibition is a potentially powerful therapeutic approach for children suffering an incurable disease that requires a lifetime of support and care. It is surprising, given the suppression of other phenotypes, that Lipin deficiency has little benefit for slowed development. However, we cannot distinguish whether this truly reflects a Lipin-independent process, or whether it relates to the confound of greater lethality in "non-rescued" cKO/E mice. Alternatively, it could also relate to the fact that Lipin activity remains above normal even in "Lipin-rescued" mice.
The dominant disease of TorsinA dystonia is a movement disorder. Thus, the fact that Lipin deficiency suppresses abnormal movements in cKO/E mice suggests a pathogenic role for Lipin hyperactivity. This is also strongly supported by the fact that Lipin is abnormally regulated in fibroblasts from dystonia patients (TOR1A +/E genotype), and appears elevated in TorsinA dystonia patient iPSC-derived neurons.
Moreover, dysfunction of striatal cholinergic neurons is strongly implicated in dominant TorsinA dystonia pathogenesis (31, 36, 37), and we show here that Lipin hyperactivity has a role in their selective vulnerability to TorsinA mutation (19). Thus, these data strongly implicate Lipin hyperactivity in dominant TorsinA dystonia and predict that Lipin inhibition also represents a therapy for these patients.
The data also raise the question of why Lipin hyperactivity is neurotoxic. The mechanism differs from flies where it upregulates triglycerides and suppresses membrane lipid levels (12) . The most obvious explanation is that transient and/or locally altered levels of PtdA and/or DAG lipids inappropriately activate signaling cascades, for example impacting mTor and/or protein kinase C that are well characterized responders to PtdA and DAG, respectively (15, 38) . In addition, our data firmly establish Lipin regulation as a key role of torsin AAA+ enzymes: it encompasses fly dTorsin, human and mouse TorsinA, as well as TorsinB. This places torsins on a list of Lipin regulators that includes insulin and mechano-signaling, amongst others (29, 39, 40). How torsins biochemically execute Lipin regulation also requires additional study, but it is potentially via Lipin phosphorylation given that only phosphorylation-deficient Lipin1 mutants cause cytotoxicity in mammalian cells like occurs when TorsinA is lost.
The most important finding is the therapeutic potential of Lipin inhibition for TorsinA diseases, especially the currently untreatable recessive syndrome. Indeed, an overactive enzyme is amongst the most feasible of druggable targets. The fact we see benefit from relatively mild Lipin inhibition (mediated by the Lipin1+/-genotype) is also crucial: this degree of Lipin inhibition is tolerated by mice, as well as humans.
Currently there are no small molecules known to inhibit Lipin specifically or with high affinity, and those in experimental use hit other targets with orders of magnitude higher affinity (41, 42). Nevertheless, Lipin has high specificity for a single substrate molecule (PtdA) and belongs to a relatively unstudied and unexploited class of phosphatases (43). This suggests that Lipin inhibition is a realistic druggable target and, given the data presented here, can provide powerful therapeutic benefit for currently incurable conditions that have such severe symptoms to be lethal. Competing interests: Authors declare no competing interests.
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All data is available in the main text or the supplementary materials.
Methods: Mouse Husbandry and Tissue Collection
Lipin1, Tor1a and Nestin-Cre mice are previously described (17, 18, 24, 46) and/ or acquired from Jackson Mice (Bar Harbour, ME). Genotyping was performed as previously described or by TransnetYX (Memphis, TN). The days of embryonic development were defined after assigning the day of vaginal plug detection as E0.5.
Embryos were collected from pregnant females after they were euthanized by cervical dislocation. Days of post-natal development were defined with the birthdate as P0.
Postnatal animals were permanently identified using the AIMS Pup Tattoo
Identification System (Budd Lake, NJ). Tissues were collected from post-natal animals after decapitation (P0 until P14), cervical dislocation (P14 until P35), or CO2 inhalation.
Tissue destined for biochemical analysis was snap frozen and stored at -80°C until use. Tissues destined for histological analysis were perfused and fixed overnight at 4°C in 4% paraformaldehyde in phosphate buffered saline (PBS). They were then either dehydrated and embedded in paraffin or cryoprotected in 30% sucrose, placed in embedding media, rapidly frozen on dry ice, and stored at -80°C until required. unable to straighten its spine during ambulation or at rest. All tests were performed with all mice that had been cohoused and observers were blind to genotype. While cKO/E animals could be distinguished by reduced weight, this could not discriminate their Lipin1 genotype. After weaning (P21) we continued to examine animals for overall health, including weighing every fourth day.
Cell Lines and Electroporation
Mouse embryonic fibroblasts were produced from E13.5 embryos using standard conditions, and transformed by transfection with a plasmid encoding the SV40 large tumor-antigen, followed by > 10 rounds of passaging, and storing in liquid N2 until use.
shRNA plasmids were electroporated Gene Pulser Xcell™, and cells harvested 72- 
Plasmids
ShRNA plasmids used were acquired from Sigma: Tor1b (TRCN0000106485), scrambled control (Empty pLKO.1), and TOR1B (TRCN0000159398). We used
Gibson cloning (NEB) to generate plasmids that express mouse Lipin1 fused at the Cterminus with mCherry. We PCR amplified Lipin1 (lacking a stop codon) and mCherry cDNA sequences and fused these in-frame between the Xho1 and BglII sites of pBudCE4.1 (Invitrogen). Lipin1 sequences were amplified from the following plasmids:
pRK5 FLAG 17xS/T->A, catalytic active lipin 1 (Addgene #32007), pRK5 FLAG wildtype, catalytic active lipin 1 (#32005), pRK5 FLAG 17xS/T->A, catalytic dead lipin 1 (#32008), pRK5 FLAG wildtype, catalytic dead lipin 1 (#32005).
Patient cells, iPSC reprogramming, culturing and differentiation
We included two dystonia patients carrying the +/ΔE mutation in TorsinA (one male and one female) and four healthy control individuals. Skin biopsies for functional assays were taken from each individual. The study was approved by the local ethics committee of the University of Lübeck and all participants gave written informed consent. Two patient skin fibroblast lines were reprogrammed into iPSCs using Sendai virus to deliver the four reprogramming factors OCT4, SOX2, KLF4, and cMYC 
RNAseq

Sample Preparation and Sequencing
Library preparation, sequencing and statistical data analysis were performed by the VIB Nucleomics Core (www.nucleomics.be). RNA concentration and purity were determined spectrophotometrically using the Nanodrop ND-1000 (Nanodrop Technologies) and RNA integrity was assessed using a Bioanalyser 2100 (Agilent).
Per sample, an amount of 500 ng of total RNA was used as input. Using the Illumina TruSeq® Stranded mRNA Sample Prep Kit (Part # 15031048 Rev E. October 2013), poly-A containing mRNA molecules were purified from the total RNA input using poly-T oligo-attached magnetic beads. In a reverse transcription reaction using random primers, RNA was converted into first strand cDNA and subsequently converted into double-stranded cDNA in a second strand cDNA synthesis reaction using DNA Polymerase I and RNAse H. The cDNA fragments were extended with a single 'A' base to the 3' ends of the blunt-ended cDNA fragments after which multiple indexing adapters were ligated introducing different barcodes for each sample. Finally, enrichment PCR (12 cycles) was carried out to enrich those DNA fragments that have adapter molecules on both ends and to amplify the amount of DNA in the library.
Sequence-libraries of each sample were equimolarly pooled and sequenced on Illumina NextSeq500 flow-cells with a High Output 75bp kit (Single Read -1.2pM Pool + 1.89% PhiX v3) at the VIB Nucleomics core (www.nucleomics.be).
Data analysis
Preprocessing: Low quality ends and adapter sequences were trimmed off from the Illumina reads with FastX 0.0.14 and Cutadapt 1.7.1 (53, 54). Subsequently, small reads (length < 35 bp), polyA-reads (more than 90 % of the bases equal A), ambiguous reads (containing N), low-quality reads (more than 50 % of the bases < Q25) and artifact reads (all but three bases in the read equal one base type) were filtered using using FastX 0.0.14 and ShortRead 1.24.0 (55). With Bowtie2 2.2.4 we identified and removed reads that align to phix_illumina (56).
Mapping:
The preprocessed reads were aligned with STAR aligner v2.4.1d to the reference genome of Mus musculus (GRCm38.73) (57). Default STAR aligner parameter settings were used, except for '--outSAMprimaryFlag OneBestScore --twopassMode Basic --alignIntronMin 50 --alignIntronMax 500000 --outSAMtype BAM SortedByCoordinate'. Using Samtools 1.1, reads with a mapping quality smaller than 20 were removed from the alignments (58).
Counting: The number of reads in the alignments that overlap with gene features were counted with featureCounts 1.4.6 (59). Following parameters were chosen: -Q 0 -s 2 -t exon -g gene_id. We removed genes for which all samples had less than 1 countper-million. Raw counts were further corrected within samples for GC-content and between samples using full quantile normalization, as implemented in the EDASeq package from Bioconductor (60).
Differential gene expression:
With the EdgeR 3.8.6 package of Bioconductor, a negative binomial generalized linear model (GLM) was fitted against the normalized counts (61). We did not use the normalized counts directly, but worked with offsets.
Differential expression was tested for with a GLM likelihood ratio test, also implemented in the EdgeR package. To select the differentially expressed genes, we adopt the criterion that was used during the elaborate MAQC-I study (62) that selected genes based on uncorrected p-value < 0.001 and a fold change >2.
qRT-PCR
Cells preserved in RNAlater were disrupted and homogenized in RLT buffer using a QIAshredder, followed by RNA isolation according to the manufacturer's instructions (RNeasy Qiagen Mini Kit; all Qiagen). cDNA was generated using SuperScript IV Reverse Transcriptase (Invitrogen) and 50μM random hexamer priming. cDNA was 
